

Are you currently being treated for **ALK+** NSCLC, and planning for the next step in your treatment journey?

Talk to your doctor today to find out whether you or a loved one may be eligible to receive NVL-655 through the ALKOVE-1 clinical trial.

ALKOVE-1 is open and enrolling patients. For more information, visit www.clinicaltrials.gov (NCT05384626), or reach out to medical@nuvalent.com.

NVL-655 is an investigational drug and has not received marketing approval by any regulatory authorities.



PRECISELY
^ Targeted Therapies for patients with cancer



A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring **ALK** Rearrangement or Activating **ALK** Mutation

ClinicalTrials.gov identifier: NCT05384626

Eligible Patients

- ✓ Age \geq 18 years old (*for Phase 1 portion only*)
- ✓ Any advanced solid tumor, including Non-Small Cell Lung Cancer (NSCLC)
- ✓ Have an ALK rearrangement or mutation
- ✓ Must have prior anticancer treatment

ALK Targeted Therapies

Tumor cells that are “ALK-positive” (ALK+) carry changes in the ALK gene, identified through cancer genomic testing. Certain genomic alterations like ALK rearrangements or mutations can drive tumor growth and survival. These are known as “driver alterations” and are critical targets for cancer therapy. NVL-655 is designed with the goal of inhibiting ALK even in the presence of mutations that enable resistance to other therapies.

Cancer Genomic Testing

Identifying your tumor’s specific driver alterations can help your doctor design a matched precision treatment plan for you.

If you have been diagnosed with NSCLC or another solid tumor and are not sure if your tumor has been genomically tested, ask your doctor today about testing options available to you.